Trial Profile
A Double-blind, Placebo-controlled, Positive Controlled, Randomized, Crossover Study to Investigate the Cardiovascular Safety of Apricitabine in Healthy Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Jun 2011
Price :
$35
*
At a glance
- Drugs Apricitabine (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions
- Sponsors Avexa
- 15 Oct 2006 New trial record.